RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
202 hedge funds and large institutions have $3.05B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 69 increasing their positions, 65 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
202
Holders Change
+16
Holders Change %
+8.6%
% of All Funds
3.58%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.16%
New
49
Increased
69
Reduced
65
Closed
32
Calls
$17.8M
Puts
$44.5M
Net Calls
-$26.7M
Net Calls Change
-$34.1M
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
$220M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
$537M |
| 3 |
CA
Corriente Advisors
Fort Worth,
Texas
|
$64.9M |
| 4 |
DFO
Duquesne Family Office
New York
|
$92.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
$287M |
Top Sellers
| 1 |
CI
CPMG Inc
Dallas,
Texas
|
$358M |
| 2 |
Millennium Management
New York
|
$19M |
| 3 |
DM
Deerfield Management
New York
|
$39.6M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
$43.6M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
$1.5M |
